A detailed history of Seven Eight Capital, LP transactions in Guardant Health, Inc. stock. As of the latest transaction made, Seven Eight Capital, LP holds 66,307 shares of GH stock, worth $3.12 Million. This represents 0.14% of its overall portfolio holdings.

Number of Shares
66,307
Holding current value
$3.12 Million
% of portfolio
0.14%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$22.3 - $36.29 $1.48 Million - $2.41 Million
66,307 New
66,307 $1.52 Million
Q4 2023

Feb 13, 2024

SELL
$21.58 - $29.5 $1.56 Million - $2.13 Million
-72,345 Reduced 84.31%
13,464 $364,000
Q3 2023

Nov 14, 2023

BUY
$25.8 - $39.97 $159,779 - $247,534
6,193 Added 7.78%
85,809 $2.54 Million
Q2 2023

Aug 14, 2023

BUY
$20.94 - $38.01 $1.25 Million - $2.26 Million
59,490 Added 295.59%
79,616 $2.85 Million
Q1 2023

May 12, 2023

SELL
$22.92 - $33.76 $1.5 Million - $2.21 Million
-65,354 Reduced 76.46%
20,126 $471,000
Q4 2022

Feb 13, 2023

BUY
$25.44 - $59.78 $2.17 Million - $5.11 Million
85,480 New
85,480 $2.33 Million
Q3 2021

Nov 15, 2021

SELL
$98.77 - $132.17 $1.02 Million - $1.36 Million
-10,282 Closed
0 $0
Q2 2021

Aug 13, 2021

SELL
$109.77 - $165.68 $611,967 - $923,666
-5,575 Reduced 35.16%
10,282 $1.28 Million
Q4 2020

Feb 09, 2021

BUY
$99.96 - $135.93 $1.59 Million - $2.16 Million
15,857 New
15,857 $2.04 Million
Q4 2019

Feb 13, 2020

SELL
$59.49 - $82.78 $2.86 Million - $3.99 Million
-48,142 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$62.59 - $110.3 $3.01 Million - $5.31 Million
48,142 New
48,142 $3.07 Million
Q2 2019

Aug 12, 2019

SELL
$63.94 - $91.11 $1.05 Million - $1.49 Million
-16,383 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$34.3 - $97.98 $561,936 - $1.61 Million
16,383 New
16,383 $1.26 Million

Others Institutions Holding GH

About Guardant Health, Inc.


  • Ticker GH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 102,220,000
  • Market Cap $4.8B
  • Description
  • Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a cl...
More about GH
Track This Portfolio

Track Seven Eight Capital, LP Portfolio

Follow Seven Eight Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Seven Eight Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Seven Eight Capital, LP with notifications on news.